Free Trial
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.59
-1.9%		$0.73
$0.55
▼
$1.69
$7.61M1.66265,165 shs116,521 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Longeveron Inc. stock logo
LGVN
Longeveron
$2.45
-1.2%		$5.56
$2.30
▼
$12.30
$7.91M-0.19185,617 shs34,699 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.20
+0.3%		$0.27
$0.08
▼
$0.91
$6.85M0.485.74 million shs103,442 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-1.87%-12.21%-23.37%-18.57%-58.23%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.70%
Longeveron Inc. stock logo
LGVN
Longeveron
-1.21%-2.39%-66.58%-60.63%-69.85%
OSR Holdings, Inc. stock logo
OSRH
OSR
+0.26%-18.81%+2.89%-46.01%-64.76%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$0.59
-1.9%		$0.73
$0.55
▼
$1.69
$7.61M1.66265,165 shs116,521 shs
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
Longeveron Inc. stock logo
LGVN
Longeveron
$2.45
-1.2%		$5.56
$2.30
▼
$12.30
$7.91M-0.19185,617 shs34,699 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.20
+0.3%		$0.27
$0.08
▼
$0.91
$6.85M0.485.74 million shs103,442 shs
10 Best Stocks to Own in Fall 2026 Cover
10 Best Stocks to Own in Fall 2026

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-1.87%-12.21%-23.37%-18.57%-58.23%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.70%
Longeveron Inc. stock logo
LGVN
Longeveron
-1.21%-2.39%-66.58%-60.63%-69.85%
OSR Holdings, Inc. stock logo
OSRH
OSR
+0.26%-18.81%+2.89%-46.01%-64.76%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
2.40
Hold$3.07417.06% Upside
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
1.50
ReduceN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
2.00
Hold$80.003,165.31% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CLSD, APRE, OSRH, and LGVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/25/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/13/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$3.00
8/11/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/28/2026
Longeveron Inc. stock logo
LGVN
Longeveron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
$290K25.75N/AN/A$1.52 per share0.39
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
Longeveron Inc. stock logo
LGVN
Longeveron
$1.20M6.51N/AN/A$2.47 per share0.99
OSR Holdings, Inc. stock logo
OSRH
OSR
$1.81M3.80N/AN/A$3.56 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$12.60M-$1.08N/AN/AN/AN/A-47.60%-40.97%11/11/2026 (Estimated)
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A
Longeveron Inc. stock logo
LGVN
Longeveron
-$22.70M-$9.90N/AN/AN/A-1,977.59%-223.19%-150.20%11/3/2026 (Estimated)
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.37N/AN/AN/A-593.15%-8.36%-6.24%N/A

Latest CLSD, APRE, OSRH, and LGVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Longeveron Inc. stock logo
LGVN
Longeveron
-$1.95N/AN/AN/A$0.56 millionN/A
8/14/2026Q2 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.02N/A-$0.02N/A$0.32 million
8/12/2026Q2 2026
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
-$0.1775-$0.07+$0.1075-$0.07$0.25 millionN/A
8/12/2026Q2 2026
Longeveron Inc. stock logo
LGVN
Longeveron
-$1.75-$0.19+$1.56-$1.90$0.33 million$0.29 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/AN/AN/AN/AN/A
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
Longeveron Inc. stock logo
LGVN
Longeveron
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
N/A
13.56
13.56
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87
Longeveron Inc. stock logo
LGVN
Longeveron
N/A
2.63
2.63
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.18
0.14

Institutional Ownership

CompanyInstitutional Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
34.19%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
Longeveron Inc. stock logo
LGVN
Longeveron
10.01%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%

Insider Ownership

CompanyInsider Ownership
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
10.49%
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
Longeveron Inc. stock logo
LGVN
Longeveron
7.42%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aprea Therapeutics, Inc. stock logo
APRE
Aprea Therapeutics
812.59 million11.27 millionNo Data
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable
Longeveron Inc. stock logo
LGVN
Longeveron
383.19 million2.95 millionNot Optionable
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A

Recent News About These Companies

Inhibrx Biosciences (NASDAQ:INBX) and OSR (NASDAQ:OSRH) Financial Comparison
October 12 at 4:45 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109796
Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
August 27, 2026  |  accessnewswire.comA
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
August 21, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69356686-osr-health-inc-osr-health-receives-nasdaq-staff-delisting-determination-and-intends-to-request-hearings-panel-appeal-200.htm
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 19, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69351809-osr-health-inc-osr-health-sees-global-shareholder-momentum-at-critical-inflection-point-200.htm
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026  |  accessnewswire.comA
OSR Holdings Stock Price History
August 18, 2026  |  investing.comhttps://www.investing.com/equities/bellevue-life-sciences-acq-historical-data
OSR Health Inc (OSRH) Stock Price, Quote, News & History
August 11, 2026  |  benzinga.comhttps://www.benzinga.com/quote/OSRH
OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277330-osr-health-inc-osr-health-ceo-reaffirms-confidence-and-highlights-subsidiary-business-development-200.htm
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
August 11, 2026  |  accessnewswire.comA
OSR Health Inc.
August 9, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/osrh/financials/cash-flow
OSRH OSR Health, Inc.
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/OSRH/sec-filings
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7, 2026  |  accessnewswire.comA
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
August 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69186987-osr-health-inc-osr-health-secures-nasdaq-communication-loyalty-cvr-program-will-not-trigger-a-price-adjustment-200.htm
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026  |  accessnewswire.comA
OSR Health, A Message From the CEO
July 13, 2026  |  accessnewswire.comA
OSR Health Earnings Estimates, EPS & Revenue | NASDAQ:OSRH
July 6, 2026  |  benzinga.comhttps://www.benzinga.com/quote/OSRH/earnings
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/correction-source-emerging-growth-research-170500642.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aprea Therapeutics stock logo

Aprea Therapeutics NASDAQ:APRE

$0.59 -0.01 (-1.87%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$0.59 0.00 (-0.69%)
As of 10/12/2026 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Longeveron stock logo

Longeveron NASDAQ:LGVN

$2.45 -0.03 (-1.21%)
Closing price 10/12/2026 04:00 PM Eastern
Extended Trading
$2.43 -0.02 (-0.94%)
As of 10/12/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

OSR stock logo

OSR NASDAQ:OSRH

$0.20 +0.00 (+0.26%)
As of 10/12/2026 03:33 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas